CobiCure Grant Drives Advancement: Revolutionary Non-Surgical Heart Valve for Pediatric Congenital Heart Disease Unveiled
Wednesday, August 30, 2023
CobiCure Medical Technologies, a non-profit organization focused on advancing pediatric healthcare solutions, has announced its unwavering commitment to addressing the gaps in pediatric medical technology. As part of the Advancium Health Network, CobiCure is taking proactive steps by providing strategic support, essential resources. A Houston-based medical device company. PolyVascular is dedicated to revolutionizing treatment options for young children who suffer from congenital heart disease, with the development of a groundbreaking non-surgical heart valve a first-of-its-kind innovation.
The collaboration between CobiCure MedTech and PolyVascular is aimed at propelling the development of PolyVascular's pioneering polymer-based heart valve. This support is geared towards preparing the technology for upcoming human clinical trials, setting the stage for a significant advancement in the treatment of congenital heart disease in children. According to statistics from the Centers for Disease Control and Prevention (CDC), nearly 40,000 births each year are affected by congenital heart defects.
CobiCure's aligned mission, strategic framework, and valuable resources are seamlessly integrated with PolyVascular's vision to eliminate the need for invasive surgeries in pediatric congenital heart cases. PolyVascular stands at the forefront of medical innovation, dedicated to developing an advanced heart valve replacement specifically designed for children afflicted by congenital heart disease. The company's pioneering approach involves the creation of a non-surgical heart valve using innovative polymer materials. This revolutionary approach not only reduces the need for multiple surgeries but also significantly enhances the overall quality of life for affected patients.